Others have previously explored whether miRNA-221 levels in circulating blood can be used as a biomarker for the diagnosis and prognosis of NKTCL [6], and shown that miRNA-146a downregulates the activity of NF-KB by regulating the target molecule TRAF6, which is a tumor suppressor gene in NKTCL and is related to patient prognosis [7]. Here, TRAF6 is linked to extranodal nasal NK/T cell lymphoma.